Recent advances in lung cancer treatment have demonstrated significant responses in patients when they were treated with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies (Lahiri et al., 2023). Here, CD274 is linked to lung carcinoma.